Table 1.

Ongoing clinical trials evaluating the available systemic treatments in lung carcinoids

Systemic treatment	Study identifier	Study title	Study design	Population	Intervention	Primary endpoint
SSAs	NCT02683941	SPINET	Phase 3 Randomized double-blind	TCs and ACs	Lanreotide + BSC vs PCB + BSC	DCR
	NCT02698410	ATLANT	Phase 2 Single arm Open-label	TCs and ACs	Lanreotide + TMZ	PFS
	NCT02823691	MetNET-2	Early Phase 1	Advanced GI-NENs and lung carcinoids	Lanreotide + metformin	Safety
PRRT	NCT03466216	–	Phase 1	SSTRs positive advanced NENs	AlphaMedix™	Safety and DLT
	NCT03273712	–	Phase 2 Single arm Open-label	SSTRs positive advanced NENs	[Yttrium-90-DOTA]TOC	ORR and safety
	NCT03454763	LUTHREE	Phase 2 Randomized Open-label	SSTRs positive advanced NENs	[Lutetium-177-DOTA]TATE every 5 week (intensive) vs Lutetium-177-DOTA]TATE every 8–10 week (no intensive)	PFS and safety
	NCT02754297	P-PRRT	Phase 2 Single arm Open-label	SSTRs positive advanced NENs	[Lutetium-177-DOTA]TOC	ORR
Everolimus	NCT03629847	–	Phase 1–2 Single arm Open-label	SSTRs positive advanced NENs	Everolimus + [Lutetium-177-DOTA]TATE	Safety
	NCT03670030	–	Phase 2 Single arm Open-label	Advanced well differentiated NENs	ABI-009	ORR
CHT	NCT02698410	ATLANT	Phase 2 Single arm Open-label	TCs and ACs	Lanreotide + temozolomide	DCR
	NCT03217097	MGMT-NET	Phase 4 Randomized Open-label	Advanced well differentiated lung, duodenopancreatic and unknown origin NENs	Oxaliplatin vs temozolomide	ORR

TCs typical carcinoids, ACs atypical carcinoids, PCB placebo, BSC best supportive care, TMZ temozolomide, DCR disease control rate, PFS progression free survival, GI gastrointestinal, SSTRs somatostatin receptors, ORR objective response rate, CHT chemotherapy